Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Dalteparin may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining dalteparin with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining dalteparin with radiation therapy in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.
Key facts
- Study ID
- NCT00028678
- Run by
- Eastern Cooperative Oncology Group
- People needed
- 45
- Starts
- 2002-07-11
- Expected to finish
- 2007-06-01
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- CCOP - Carle Cancer Center — Urbana, Illinois, United States
- CCOP - Kalamazoo — Kalamazoo, Michigan, United States
- West Michigan Cancer Center — Kalamazoo, Michigan, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- CCOP - Metro-Minnesota — Saint Louis Park, Minnesota, United States
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- CCOP - Oklahoma — Tulsa, Oklahoma, United States
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center — Nashville, Tennessee, United States
- CCOP - Scott and White Hospital — Temple, Texas, United States
- CCOP - St. Vincent Hospital Cancer Center, Green Bay — Green Bay, Wisconsin, United States
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.